阿尔法阻断剂对预测BPH患者LUTS改善的立即作用
Prashant Sevach1, Govind Sharma1, Shivam Priyadarshi1
1Department of Urology and Renal Transplant, SMS Medical College, Jaipur, Rajasthan, India.
Urologia
|August 22, 2023
概括
塔姆苏洛辛和西洛多辛等α阻塞剂有效地改善尿液流动,并减少良性前列腺增生症 (BPH) 患者的症状. 第一个剂量显示了立即的益处,预测了下尿路症状 (LUTS) 的中期积极结果.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 药理学 药理学是指药理学的学科.
- 医学科学 医学科学 医学科学
背景情况:
- 良性前列腺增生症 (BPH) 是老年男性常见的疾病,其特征是下泌尿道症状 (LUTS).
- 阿尔法阻断剂是BPH的主要药理疗法,因为它们在缓解LUTS方面具有有效性,成本效益和耐受性.
- 研究特定α阻断剂的直接和中期影响对于优化BPH管理至关重要.
研究的目的:
- 评估第一剂α阻断剂药物对患有良性前列腺增生症 (BPH) 患者下泌尿道症状 (LUTS) 的直接影响.
- 为了比较tamsulosin和silodosin在改善尿液流速 (UFM) 和国际前列腺症状评分 (IPSS) 的有效性.
- 评估对阿尔法抑制剂的初始反应对中期治疗结果的预测价值.
主要方法:
- 一项涉及100名BPH患者的比较研究,随机分为两组:A组 (tamsulosin) 和B组 (silodosin),每组50名患者.
- 基线评估包括病史,数字直肠检查 (DRE),尿液流量计 (UFM),脏,尿道,膀和空白后残留 (PVR) 体积的超声波,IPSS,血清前列腺特异抗原 (PSA),血清肌素,尿液分析和尿液培养.
- 这些参数在启动α阻断剂治疗1周,1个月,3个月后重新评估,以比较与基线的变化.
主要成果:
- 坦苏洛辛和西洛多辛在所有后续检查中显著改善了平均尿流量测量 (Qmax) 和与基线相比的排泄时间 (p < 0.001).
- 在两组中,平均Qmax显著增加,A组的值达到15.66 ± 3.18秒,B组的值达到15.18 ± 3.18秒.
- 在两组治疗中,平均空虚后残留量 (PVR) 和国际前列腺症状得分 (IPSS) 也有所改善.
结论:
- 坦苏洛辛和西洛多辛的初始剂量表明,在BPH相关的LUTS患者中,尿液流量计 (UFM) 和国际前列腺症状评分 (IPSS) 的快速和显著改善.
- 这种对α阻断剂治疗的早期积极反应是有利的中期治疗结果的可靠预测指标.
- 阿尔法阻断剂被证实是BPH管理中立即和持续缓解LUTS的有效药物.
相关概念视频
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
887
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
887
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
890
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
890
Antianginal Drugs: Nitrates and β-Blockers
642
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
642
Heart Failure Drugs: β-Blockers
364
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
364
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
187
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
187
Adrenergic Antagonists: ɑ and β-Receptor Blockers
511
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
511


